These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24535265)

  • 1. The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer.
    Xiong T; Yang J; Wang H; Wu F; Liu Y; Xu R; Lv Z; Xue P; Cao W; Zhang Y
    Mol Biol Rep; 2014; 41(4):2629-34. PubMed ID: 24535265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.
    Cui J; Li D; Shen L; Zhang W; Xu X
    Tumour Biol; 2014 Jul; 35(7):6335-41. PubMed ID: 24652592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.
    Yuan H; Niu YM; Wang RX; Li HZ; Chen N
    Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
    Stern MC; Johnson LR; Bell DA; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
    Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
    Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
    Ding DP; Ma WL; He XF; Zhang Y
    Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
    Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
    Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls.
    Li S; Zeng XT; Ruan XL; Liu TZ; Wang XH
    Mol Biol Rep; 2014 Jun; 41(6):3621-9. PubMed ID: 24510389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis.
    Li C; Jiang Z; Liu X
    Mol Biol Rep; 2010 Jan; 37(1):301-9. PubMed ID: 19669592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XRCC3 Thr241Met and XPD Lys751Gln gene polymorphisms and risk of clear cell renal cell carcinoma.
    Loghin A; Bănescu C; Nechifor-Boila A; Chibelean C; Orsolya M; Nechifor-Boila A; Tripon F; Voidazan S; Borda A
    Cancer Biomark; 2016; 16(2):211-7. PubMed ID: 26682510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.
    Qiu LX; Yao L; Zhang J; Zhu XD; Zhao XM; Xue K; Mao C; Chen B; Zhan P; Yuan H; Hu XC
    Breast Cancer Res Treat; 2010 Nov; 124(1):229-35. PubMed ID: 20204500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects.
    Lin H; Lin D; Zheng C
    Diagn Pathol; 2014 Jan; 9():15. PubMed ID: 24443924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis.
    Zhang T; Zhang DM; Zhao D; Hou XM; Ma SC; Liu XJ
    Onco Targets Ther; 2014; 7():1255-60. PubMed ID: 25050067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk.
    Schabath MB; Delclos GL; Grossman HB; Wang Y; Lerner SP; Chamberlain RM; Spitz MR; Wu X
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):878-84. PubMed ID: 15824159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis.
    Zhang RC; Mou SH
    Tumour Biol; 2013 Apr; 34(2):901-7. PubMed ID: 23271362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk.
    Liu C; Yin Q; Hu J; Weng J; Wang Y
    Tumour Biol; 2014 Feb; 35(2):1203-9. PubMed ID: 24061640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
    Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
    J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies.
    Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y
    J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
    Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
    Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.